Characterization of the Phenotypic Markers of B Cell Lymphocytes in Rheumatoid Arthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-03

Study Completion Date

2020-08-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rheumatoid Arthritis (RA):

RA is a chronic inflammatory autoimmune disease that primarily affects the small joints, eventually leading to bone erosion and an inability to move (1). Several immune cells participate in the pathogenesis of RA. One of those cells is B cell.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detection of Pathological Lymphocytes in Patients With Autoimmune Disease

NCT02813083

Arthritis, Rheumatoid

COMPLETED

Alterations in CD8αβ and CD8αα T Cell Levels in Patients With Rheumatoid Arthritis

NCT05827562

Rheumatoid Arthritis

NOT_YET_RECRUITING

Study of Some Risk Factors for Developing RA

NCT03624179

Rheumatoid Arthritis

UNKNOWN

Periodontal Inflammation and Immunity in Preclinical Rheumatoid Arthritis

NCT02794012

Rheumatoid Arthritis Periodontal Disease

COMPLETED

Can Cytokines be Used as an Activation Marker

NCT04486027

Rheumatoid Arthritis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

B cell population:

B lymphocytes play several critical roles in the pathogenesis of rheumatoid arthritis. They are the source of the rheumatoid factors (RF) and anti-cyclic-citrullinated peptide (anti-CCP), which contribute to immune complex formation and complement activation in the joints (2).

There is different B cell subpopulation according to the stage of maturation and activity. Distinction of this subpopulation can be done by detection of different CD molecules expressed on cell surface (3). From all sub-population this research will focus on these immunophenotypes; immature, mature, memory and B-reg cells by using CD 19, CD24, CD38 \& CD27 respectively.

Joa˜ o E. Fonseca and his team found the reduction in B cell subpopulation especially (Pre- switched memory B cells) both in RA and Arthritis in the early stage. This observation not related to using methotrexate or corticosteroid in the treatment. They used the classification of B cells with CD 19 mainly and then IgD and CD27 to identify B cells (4).

Gabriella Sármay team found that the number of B-reg CD19+ CD27+ IL-10+ cells in peripheral blood is fewer in RA patients compared with healthy controls (5).

Interleukin 10:

Interleukin (IL)-10 functions as an anti-inflammatory cytokine in rheumatoid arthritis. IL-10 mRNA levels were significantly elevated in synovial fluid mononuclear cells (SFMCs) from patients with RA compared with PBMCs peripheral blood mononuclear cells (PBMCs) from RA patients or healthy volunteers according to Isomäki P (6).

IL 10 is primarily produced by monocytes mainly and, then by lymphocytes; type 2 T helper cells (TH2), mast cells, CD4+CD25+Foxp3+ regulatory T cells, and in a certain subset of activated T cells and B cells (7).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autoimmune Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients

1\. Group 1: 30 diseased with Early Rheumatoid Arthritis from 6months to 1 year).

drugs described in the clinic.

for patients and healthy donors

Intervention Type DIAGNOSTIC_TEST

1. Detection of (CD19, CD24, CD38 \& CD27) markers in peripheral blood samples by Flow Cytometry
2. Determine the serum level of IL 10 using ELISA plate

patients 2

2\. Group 2: 30 diseased with late/chronic Rheumatoid Arthritis. drugs described in the clinic.

for patients and healthy donors

Intervention Type DIAGNOSTIC_TEST

1. Detection of (CD19, CD24, CD38 \& CD27) markers in peripheral blood samples by Flow Cytometry
2. Determine the serum level of IL 10 using ELISA plate

healthy donors

3\. Group 3: 30 healthy controls. No drugs.

for patients and healthy donors

Intervention Type DIAGNOSTIC_TEST

1. Detection of (CD19, CD24, CD38 \& CD27) markers in peripheral blood samples by Flow Cytometry
2. Determine the serum level of IL 10 using ELISA plate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

for patients and healthy donors

1. Detection of (CD19, CD24, CD38 \& CD27) markers in peripheral blood samples by Flow Cytometry
2. Determine the serum level of IL 10 using ELISA plate

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient diagnosed as Rheumatoid arthritis that fulfilled ACR/EULAR Criteria (American College of Rheumatology/European League Against Rheumatism).
* (8) Age \>18 Years.